Literature DB >> 22680765

2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.

Daniel A Pollyea, Holbrook E Kohrt, Bing Zhang, James Zehnder, David Schenkein, Valeria Fantin, Kimberly Straley, Aparna Vasanthakumar, Omar Abdel-Wahab, Ross Levine, Lucy A Godley, Bruno C Medeiros.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22680765      PMCID： PMC3688062          DOI： 10.3109/10428194.2012.701009

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  9 in total

1.  Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.

Authors:  Elodie Pronier; Carole Almire; Hayat Mokrani; Aparna Vasanthakumar; Audrey Simon; Barbara da Costa Reis Monte Mor; Aline Massé; Jean-Pierre Le Couédic; Frédéric Pendino; Bruno Carbonne; Jérôme Larghero; Jean-Luc Ravanat; Nicole Casadevall; Olivier A Bernard; Nathalie Droin; Eric Solary; Lucy A Godley; William Vainchenker; Isabelle Plo; François Delhommeau
Journal:  Blood       Date:  2011-07-06       Impact factor: 22.113

2.  Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.

Authors:  D A Pollyea; H E Kohrt; L Gallegos; M E Figueroa; O Abdel-Wahab; B Zhang; S Bhattacharya; J Zehnder; M Liedtke; J R Gotlib; S Coutre; C Berube; A Melnick; R Levine; B S Mitchell; B C Medeiros
Journal:  Leukemia       Date:  2011-10-28       Impact factor: 11.528

Review 3.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

4.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

5.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

6.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

7.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

8.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

9.  Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification.

Authors:  Shinsuke Ito; Ana C D'Alessio; Olena V Taranova; Kwonho Hong; Lawrence C Sowers; Yi Zhang
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962
  9 in total
  9 in total

Review 1.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

Review 2.  Targeting minimal residual disease: a path to cure?

Authors:  Marlise R Luskin; Mark A Murakami; Scott R Manalis; David M Weinstock
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

Review 3.  Oncometabolites: linking altered metabolism with cancer.

Authors:  Ming Yang; Tomoyoshi Soga; Patrick J Pollard
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 4.  Isocitrate dehydrogenase mutations in leukemia.

Authors:  Anna Sophia McKenney; Ross L Levine
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 19.456

5.  Alterations of 5-hydroxymethylcytosine in human cancers.

Authors:  Christopher J Mariani; Jozef Madzo; Erika L Moen; Ali Yesilkanal; Lucy A Godley
Journal:  Cancers (Basel)       Date:  2013-06-25       Impact factor: 6.639

6.  Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique.

Authors:  Nadine F Voelxen; Stefan Walenta; Martin Proescholdt; Katja Dettmer; Stefan Pusch; Wolfgang Mueller-Klieser
Journal:  Front Oncol       Date:  2016-03-07       Impact factor: 6.244

7.  Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.

Authors:  Jiang-Han Wang; Wen-Lian Chen; Jun-Min Li; Song-Fang Wu; Tian-Lu Chen; Yong-Mei Zhu; Wei-Na Zhang; Yang Li; Yun-Ping Qiu; Ai-Hua Zhao; Jian-Qing Mi; Jie Jin; Yun-Gui Wang; Qiu-Ling Ma; He Huang; De-Pei Wu; Qin-Rong Wang; Yan Li; Xiao-Jing Yan; Jin-Song Yan; Jian-Yong Li; Shuai Wang; Xiao-Jun Huang; Bing-Shun Wang; Wei Jia; Yang Shen; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 12.779

8.  Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

Authors:  Courtney D DiNardo; Kathleen J Propert; Alison W Loren; Elisabeth Paietta; Zhuoxin Sun; Ross L Levine; Kimberly S Straley; Katharine Yen; Jay P Patel; Samuel Agresta; Omar Abdel-Wahab; Alexander E Perl; Mark R Litzow; Jacob M Rowe; Hillard M Lazarus; Hugo F Fernandez; David J Margolis; Martin S Tallman; Selina M Luger; Martin Carroll
Journal:  Blood       Date:  2013-05-02       Impact factor: 25.476

9.  Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Authors:  Yann Ferret; Nicolas Boissel; Nathalie Helevaut; Jordan Madic; Olivier Nibourel; Alice Marceau-Renaut; Maxime Bucci; Sandrine Geffroy; Karine Celli-Lebras; Sylvie Castaigne; Xavier Thomas; Christine Terré; Hervé Dombret; Claude Preudhomme; Aline Renneville
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 11.047
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.